{"result": {"id": "ac4f45c4-71b1-436f-8948-6586bcba5fad", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>阿托伐他汀钙<|>organization<|>阿托伐他汀钙是一种他汀类药物，具有显著的降血脂效果，特别是在降低低密度脂蛋白胆固醇方面表现突出，同时还能提高高密度脂蛋白胆固醇水平，促进脂质清除，减少血管壁的脂质沉积，减缓动脉硬化进程)\n##\n(\"entity\"<|>HMG-CoA 还原酶<|>organization<|>HMG-CoA 还原酶是体内合成胆固醇的关键酶，阿托伐他汀钙通过抑制该酶的活性，显著减少胆固醇的生成，从而有效降低血脂水平)\n##\n(\"entity\"<|>利尿剂<|>organization<|>利尿剂是一种可能导致血脂水平轻微升高的药物，与高血脂并存时可能加重患者病情，降低治疗效果)\n##\n(\"entity\"<|>β 受体阻滞剂<|>organization<|>β 受体阻滞剂是一种可能导致血脂水平轻微升高的药物，与高血脂并存时可能加重患者病情，降低治疗效果)\n##\n(\"relationship\"<|>阿托伐他汀钙<|>HMG-CoA 还原酶<|>阿托伐他汀钙通过抑制HMG-CoA 还原酶的活性来减少胆固醇的生成<|>8)\n##\n(\"relationship\"<|>利尿剂<|>β 受体阻滞剂<|>利尿剂和β 受体阻滞剂都是可能导致血脂水平升高的药物<|>5)\n##\n(\"relationship\"<|>阿托伐他汀钙<|>利尿剂<|>阿托伐他汀钙与利尿剂在治疗高血压合并高血脂患者时可能有不同的效果<|>3)\n##\n(\"relationship\"<|>阿托伐他汀钙<|>β 受体阻滞剂<|>阿托伐他汀钙与β 受体阻滞剂在治疗高血压合并高血脂患者时可能有不同的效果<|>3)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165547, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 413, "prompt_tokens": 2326, "total_tokens": 2739, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 534}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 些利尿剂、 β 受体阻滞剂等，可能会导致血 脂水平的轻微升高，这种药物与高血脂并存的情况无 疑加重了患者的病情，甚至可能相互作用， 降低治疗 效果。因此，单纯依赖降血压药物，可能无法达到理 想的综合治疗效果，反而会加重患者的负担。基于此，  治疗高血压合并高血脂患者时，在常规使用降压药物 的同时联合使用降脂药物，具有非常重要的意义。\n　　近年来，随着阿托伐他汀钙在临床上应用的日益  广泛，越来越多的研究证明了其在高血脂管理方面的  重要作用。阿托伐他汀钙，作为他汀类药物中的一种，  具有显著的降血脂效果，特别是在降低血液中“坏 ” 胆固醇（低密度脂蛋白）方面表现突出。通过抑制体  内合成胆固醇的关键酶——HMG-CoA 还原酶，阿托伐他  汀钙能够显著减少胆固醇的生成，从而有效降低血脂  水平。此外，它还能够提高“好 ”胆固醇（高密度脂  蛋白） 的水平，促进脂质的清除，有助于减少血管壁  的脂质沉积，减缓动脉硬化的进程。\n　　在高血压合并高血脂的患者中，阿托伐他汀钙的 应用不仅仅局限于控制血脂。研究表明，长期使用阿 托伐他汀钙能够在一定程度上降低心血管事件的发生 风险，尤其是在那些已经出现动脉硬化或心脏病危险\n\n\n　因素的患者中。通过其降脂作用，阿托伐他汀钙能够  减轻脂质斑块对血管的压迫，减少血管狭窄的可能性，  从而有效降低因血流不畅引起的心脏病和中风等严重  心脑血管疾病的发生率[6]。由此可见，阿托伐他汀钙通  过改善血脂状况，起到了降低心血管风险的重要作用。  同时阿托伐他汀钙的疗效并不仅限于血脂的调节。近  年来的研究发现，这种药物在控制血压方面也可能发  挥一定作用。高血压患者常常伴随血管内皮的功能障  碍，血管内皮是调节血管舒缩和保持血管弹性的关键。  阿托伐他汀钙不仅能通过降脂作用改善血管内皮功能， 还具有抗炎作用，能够减轻血管壁的炎症反应，促进  血管的舒张与收缩能力，从而辅助降压。阿托伐他汀  钙通过减轻血管内皮损伤、抑制炎症因子释放以及减  缓动脉粥样硬化进程，或许能够间接地改善血压水平。  这一机制\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_ccb17f54225a1cd1d16fb2bb162eb5a8e65e48f48b1882f14406cf1d47f8cfdb_v2"}